Paroxetine
Social Anxiety Disorder
Beijing Tongren HospitalSmall moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
3 Active assets in the Social Anxiety Disorder cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Acamprosate Medical University of South Carolina | Phase 4 | BB |
Vortioxetine The Medical Research Network | Phase 4 | BB |
Sertraline Yang I. Pachankis, PhD | Phase 4 | BB |
ALORADINE VistaGen Therapeutics, Inc. | Phase 3 | B |
Oxytocin University of Maryland, Baltimore | Phase 2 | B |
Seroquel® Centre for Addiction and Mental Health | N/A | D |
Duloxetine Yang I. Pachankis, PhD | D |
Same molecule, other indications
Paroxetine is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →